Evidence map›Paper›PMID 39070290›Full record

ArticleMolecular therapy. Methods & clinical development2024

Engineering single-cycle MeV vector for CRISPR-Cas9 gene editing.

Ramya Rallabandi, Brenna Sharp, Spencer Majerus, Austin Royster, Sarrianna Hoffer, Mia Ikeda, Patricia Devaux

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ramya RallabandiMayo Clinic Graduate School of Biomedical Sciences, Virology and Gene Therapy Graduate Track, Mayo Clinic, Rochester, MN 55905, USA.
Brenna SharpDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Spencer MajerusDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Austin RoysterDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Sarrianna HofferDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Mia IkedaDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Patricia DevauxDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Funding

Single non-integrating RNA vector for gene editing and reprogramming of Fanconi anemia fibroblastsR01HL147852 · NHLBI · MAYO CLINIC ROCHESTER · PI DEVAUX, PATRICIA · 2020 to 2022
$954k
Single non-integrating RNA vector for gene editing and reprogramming of Fanconi anemia fibroblastsR56HL147852 · NHLBI · MAYO CLINIC ROCHESTER · PI DEVAUX, PATRICIA · 2019 to 2019
$318k
NHLBI NIH HHS R01 HL147852NHLBI NIH HHS R56 HL147852
6 · The paper itself

Abstract

CRISPR-Cas9-mediated gene editing has vast applications in basic and clinical research and is a promising tool for several disorders. Our lab previously developed a non-integrating RNA virus, measles virus (MeV), as a single-cycle reprogramming vector by replacing the viral attachment protein with the reprogramming factors for induced pluripotent stem cell generation. Encouraged by the MeV reprogramming vector efficiency, in this study, we develop a single-cycle MeV vector to deliver the gRNA(s) and Cas9 nuclease to human cells for efficient gene editing. We show that the MeV vector achieved on-target gene editing of the reporter (

Indexed as

Cas9CRISPRgene editingHDRiPSCmeaslesNHEJviral vector

Identifiers

PMID39070290
PMCPMC11283025

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.